G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.15 USD
+0.02 (0.28%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $7.15 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 341 - 360 ( 361 total )
Company: G1 Therapeutics
Industry: Unclassified
G1 Therapeutics 2Q18 Results and Pipeline Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Promising Preliminary G1T38 Phase 1b Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Biotechnology -ASCO Presentations Roundup for Covered Companies: Part 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
G1 Could Become Number One in the CDK4/6 Market; Initiating Coverage With a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Rest of Pipeline Comes into View as Trilaciclib Regulatory Timeline Accelerates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Trilaciclib Successful in 1L SCLC, De-Risking Ph 2 Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Top Picks for 2018
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
3Q, Key Data Readouts Coming Up in Early 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
Q2; Pipeline Mostly on Track; Looking Ahead to 2018 for Key Trilaciclib Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D